adenosine triphosphate | 987-65-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: adenosine triphosphate
• 英文别名: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate；[γ-33P] ATP；[γ-32P]ATP；[gamma-32P]-ATP；ATP；R-Phycoerythrin；[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• CAS: 987-65-5；11016-17-4
• 化学式: C₁₀H₁₆N₅O₁₃P₃
• 分子量: 507.184
• InChiKey: ZKHQWZAMYRWXGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.7
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  279
• 氢给体数：
  7
• 氢受体数：
  17

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29389090
• RTECS号：
  AU7417000
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

特点

藻红蛋白具有性质稳定、荧光量子产率高、背景干扰小以及易于与生物素、抗体和糖蛋白等大分子交联等特点。作为荧光探针，它在细胞生物学、组织化学及分子生物学等领域可以代替同位素或酶进行标记。

吸收光谱

藻红蛋白的吸收带位于可见光区域，从绿色延伸至远红色波长。其吸收光谱能够在广泛激发波长范围内实现多功能性，并通过产生较大的斯托克斯位移，最大限度地减少瑞利散射光的干扰。

用途

藻红蛋白是一种用于荧光偶联的红色荧光多亚基蛋白。它具有高分辨率的荧光色素标记特性，特别适用于免疫分析技术，如活细胞染色、双标记技术和细胞分选程序。

反应信息

• 作为反应物：
  描述：

  adenosine triphosphate 、 L-苏氨酸 、 zinc(II) hydroxide 以 水 为溶剂， 生成
  参考文献：
  名称：

  Molodkin; Esina; Akhussi, Russian Journal of Inorganic Chemistry, 1996, vol. 41, # 1, p. 131 - 134

  摘要：

  DOI：

文献信息

• [EN] THERAPEUTIC APPLICATION OF TRICICLIC AROMATIC AND SATURATED BENZO(4,5)THIENO-(2,3-D)PYRIMIDINE DERIVATES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS<br/>[FR] APPLICATION THÉRAPEUTIQUE DE DÉRIVÉS TRICYCLIQUES AROMATIQUES ET SATURÉS DE LA BENZO(4,5)THIÉNO-(2,3-D)PYRIMIDINE, ET LEURS SELS THÉRAPEUTIQUEMENT ACCEPTABLES
  申请人：VICHEM CHEMIE KUTATO KFT

  公开号：WO2009104027A1

  公开（公告）日：2009-08-27

  The subject of the invention is therapeutic application of tricyclic aromatic and saturated benzo[4,5]thieno[2,3-d]pyrimidine derivatives and their therapeutically acceptable salts. The compounds according to the invention is used particularly as active agent of therapeutic preparations of tyrosine-kinase inhibiting action.

  本发明涉及三环芳香和饱和苯并[4,5]噻吩[2,3-d]嘧啶衍生物及其治疗上可接受的盐的治疗应用。根据本发明的化合物特别用作酪氨酸激酶抑制作用的治疗制剂的活性成分。
• Analytical Method and Kit
  申请人：Squirrell David James

  公开号：US20080233588A1

  公开（公告）日：2008-09-25

  Analytical methods using RNA-containing probes for the detection or analysis of nucleic acid sequences is described. These probes are contacted with a sample suspected of containing the nucleic acid sequence and if they form duplexes, they are hydrolysed. This may be done, for example during an amplification reaction. AMP generated as a result of the hydrolysis is converted to ATP. The ATP may then be detected using bioluminescent reagents. Inclusion of modified adenosine in at least one probe means that the signal arising from one probe will give rise to a different and distinguishable bioluminescent signal thus enabling the use of for example an internal control in bioluminescently-reported nucleic acid tests.

  使用含RNA探针的分析方法用于检测或分析核酸序列。这些探针与怀疑含有核酸序列的样本接触，如果它们形成双链，它们将被水解。这可以在放大反应期间完成。由于水解产生的AMP被转化为ATP。然后可以使用生物发光试剂检测ATP。至少一个探针中包含修饰腺苷意味着来自一个探针的信号将产生不同且可区分的生物发光信号，从而使得例如在生物发光报告核酸测试中使用内部对照成为可能。
• Liquid protein formulations containing thiamine pyrophosphate (TPP)
  申请人：EAGLE BIOLOGICS, INC.

  公开号：US10821184B2

  公开（公告）日：2020-11-03

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

  目前已开发出浓缩、低粘度、低容量的液体蛋白质药物制剂。此类制剂可通过皮下注射或肌肉注射快速方便地给药，而无需长时间静脉注射。这些制剂包括低分子量和/或高分子量蛋白质，如 mAbs 和有机磷。加入一种或多种有机磷后，制剂的粘度会大大降低。
• Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
  申请人：Institut Gustave-Roussy

  公开号：US10969380B2

  公开（公告）日：2021-04-06

  The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.

  本发明者发现，食人细胞在体内凋亡后会发生衰老，而肿瘤抑制蛋白 p53 是这一现象的抑制因子。因此，他们提出了研究食人过程中涉及的分子途径的新工具，例如通过测量 p53 或其剪接变体（如 Δ133TP53、TP53β、TP53γ 或 Δ40TP53）的表达水平、细胞外 ATP 的释放或嘌呤能 P2Y2 受体的活性。本发明者还证明，从接受新辅助治疗的患者身上获取的乳腺癌中检测到衰老的食人细胞与患者对治疗的良好反应呈正相关。总之，这些结果首次证明，同时检测肿瘤中的食人细胞和衰老细胞有助于诊断疾病结果和预测对癌症疾病的治疗效果。
• KOSMETISCHE ZUBEREITUNG ZUR HAUTPFLEGE
  申请人：Lengheim, Hubert

  公开号：EP2395966B1

  公开（公告）日：2016-07-06